Therapy Areas: Infectious Diseases
Acceleron names Robert K. Zeldin (MD) as CMO
9 July 2018 -

Biopharmaceutical company Acceleron Pharma Inc (NASDAQ:XLRN) revealed on Friday the election of Robert K. Zeldin, MD as chief medical officer (CMO).

In the senior position, Dr Zeldin succeeds the company's outgoing CMO, Matthew Sherman, MD, who will remain until the anticipated mid-2018 release of topline Phase 3 data from the BELIEVE trial of luspatercept in beta-thalassemia patients and will then serve in an advisory capacity for one year thereafter.

Most recently, Dr Zeldin has served as CMO as well as a member of the Executive Committee at Belgium-based Ablynx NV, with responsibility for the Medical, Regulatory, Pharmacovigilance, Clinical Operations, Biostatistics and Data Management functions and led a team of 60.

Previously, Dr Zeldin was employed as senior vice president and head of Global Clinical Development at French pharmaceutical firm Stallergenes SA, vice president and US medical franchise head, Respiratory and Dermatology at Novartis Pharmaceuticals as well as senior director of Clinical Development in worldwide regulatory affairs and clinical development in the respiratory, cardiovascular and infectious disease therapeutic areas at Merck.

Earlier in his career, Dr Zeldin was a medical officer at the US Food & Drug Administration's Center for Biologics Evaluation and Research.

Login
Username:

Password: